Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Advanced Ovarian Cancer
NCT06890338Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2025
- Primary completion
- Feb 2030
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of mirvetuximab soravtansine in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by AbbVie Inc. Primary endpoint: Objective Response by Independent Central Review. Started Nov 2025; status: recruiting.
02
Drugs
mirvetuximab soravtansine
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT06890338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06890338.